Kornimate/medical-research-clean huggingface dataset:
molecular characterization of blastocystis isolates from human by restriction fragment length polymorphism (rflp) analysis

Conditions: Blastocystis Infections

Summary: blastocystis is an anaerobic unicellular protozoal parasite infecting the gastrointestinal tract of humans and a wide range of animals. it is one of the most common enteric microorganisms with higher prevalence rates in developing than in developed countries. feco-oral is the main route of transmission where low socioeconomic conditions, poor hygienic practices, close contact with animals, and drinking contaminated water act as major risk factors. infection with blastocystis was demonstrated in both symptomatic and asymptomatic people. for a long period, blastocystis was considered a commensal organism with no pathogenic role, but recently, many studies linked it to different gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. association with irritable bowel syndrome and colorectal cancer was also reported. this study aims to: - identify subtypes of human blastocystis isolates in sohag by using rflp-pcr and provide additional information on the molecular epidemiology of this parasite in our locality.


Eligibility criteria:
inclusion criteria: * patients from outpatient clinics, sohag hospitals. exclusion criteria: * patients received antiparasitic drugs in the last two weeks

Keywords: blastocystis colorectal cancer irritable bowel syndrome
helping ease anxiety and depression following stroke

Conditions: Stroke; CVA (Cerebrovascular Accident); Anxiety; Depression

Summary: the aim of this mixed methods research is to conduct feasibility pilot testing of an existing mindfulness intervention called heads: up. the intervention is designed to help people affected by stroke self-manage symptoms of anxiety and depression.

mindfulness-based interventions are thought to help people affected by stroke (lawrence et al., 2013). helping ease anxiety and depression (heads: up) is an adapted mindfulness-based intervention for people affected by stroke (lawrence, 2019). this study aligns with the feasibility/piloting stage of the medical research council framework (craig et al., 2008) and will optimise intervention delivery and study processes, ensuring all elements are working together, ready for testing at a later stage. the aim of this mixed methods research is to conduct feasibility pilot testing of heads: up to help people affected by stroke self-manage symptoms of anxiety and depression prior to phase iii testing in future work. this stage is a non-randomised pilot study based in glasgow, united kingdom. the purpose of the pilot is to assess feasibility and acceptability of delivering heads: up, and recruitment and questionnaire data collection processes; identify any additional heads: up adaptions.

Eligibility criteria:
inclusion criteria: * have had ≥1 stroke 3-60 months previously (reflects incidence of anxiety/depression) * interested in learning skills to help them cope with self-reported anxiety and/or depression * able to speak and understand conversational english * able to identify a family member/peer who would: like to take part, can speak and understand conversational english; not participating in another trial. exclusion criteria: * prior mbsr attendance in the last three years (as this may confound results) * current participant in another trial * cannot follow a 2-stage command * ≥28 on behavioural assessment of dysexecutive syndrome (bads) scale; assesses the cognitive skills required to engage with group-based interventions (goo.gl/uumefw) * hospital anxiety and depression scale (hads); screens for anxiety and depression; used extensively in primary care research (goo.gl/ttdddw). a score of 8-10 suggests mood disorder; ≥11 indicates 'probable presence'. a total cut-off score of 11 achieves optimal balance between sensitivity and specificity, and will be used for family/peer participants who have not had a stroke. a lower cut-off score is recommended for stroke survivors i.e. 4 on each sub-scale. note: a current prescription for anxiolytics or antidepressants is not an exclusion criterion. if screening identifies a potential participant who requires gp referral, that individual may subsequently be prescribed medication; this is a feature of the pilot work. in a future trial, where participants are randomised to two arms and there is equal probability of people being on medication in each arm, it will not be an issue.

Keywords: stroke cva (cardiovascular accident) anxiety depression mindfulness mindfulness based stress reduction self-management
ambu®auragain™ versus i-gel® in obese patients

Conditions: Obese

Summary: the aim of this study is the randomized comparison of two laryngeal mask (intersurgical i-gel® and ambu®auragain™) in obese patients

since the incidence of a difficult intubation lies between 4.5% -7.5%, the search for alternative airway devices has been forced in the past. as an option, the laryngeal mask is suitable, which has been used as a universal airway with a high degree of safety in routine anesthesia. there are numbers of different laryngeal masks available which have the characteristic to insert an endotracheal tube through the ventilation lumen. the indications for these laryngeal masks can be extended due to continuous improvements in the laryngeal masks, these laryngeal masks can also be used in obese patients. obese patients generally have a 4-fold increased risk of a difficult airway, and a bmi over 35 is a predictor of a difficult tracheal intubation. there are no studies comparing the intersurgical i-gel® laryngeal mask and the ambu®auragain ™ laryngeal mask in obese patients.

Eligibility criteria:
inclusion criteria: * asa 1-3 * shoulder-/elbow-/hip-/knee- or foot - surgery * signed informed consent * bmi \> 35kg/m2 exclusion criteria: * non-sober patients (last meal \<6 h) * symptomatic reflux disease * hiatus hernia * significant cardiovascular risk factors * severe copd * gastric band or gastric bypass * disease which allows an accurate examination of the physicians (e.g. neuromuscular, mental, metabolic disease) * drug or drug abuse in the recent past * legal immaturity (incompetence) * acute disease, which calls into question the narcotic potential * patients with whom the use of a laryngeal mask is contraindicated or otherwise not possible

Keywords: obese laryngeal mask airway anaesthesia
pain management of children with appendicitis in the emergency department (er)

Conditions: Pain

Summary: the aim of this retrospective study is to determine the percentage of children with appendicitis who were given analgesics or opioids in the er, to reduce their pain.


Eligibility criteria:
inclusion criteria: * children with appendicitis exclusion criteria: -
the tolerability and pharmacokinetics of multiple doses of sph3127 in chinese healthy people

Conditions: Hypertension

Summary: this study was a single center, parallel, randomized, double blind, placebo-controlled phase ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of sph3127 tablet in healthy subjects by increasing multiple dosing

three panels(100mg, 200mg, 400mg), each consisting of eight participants (the number of individual subjects in each group was not less than 1/3 of the total number).participants begin to receive the first dose of sph3127 100mg. then participants begin to receive the second dose of sph3127 200mg,after the researchers confirmed that the 100mg dose group was safe and well tolerated.then the third dose of sph3127 400mg must wait for the result of the second dose's safety and tolerability. if the subjects during escalating dose to the biggest tolerate dose group were not well tolerated, the study must adjust the maximum dose group and fall to a low dose group to conduct another test.

Eligibility criteria:
inclusion criteria: 1. the body mass index is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value). 2. before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study 3. participant has understood the research's procedure and sign the informed consent . exclusion criteria: * participant who are pregnancy, lactating women, and planned trials begin within six months of pregnancy * participant who has abnormal physical examination, laboratory examination results and clinical significance (such as: liver function examination - aspartate aminotransferase (ast) and alanine aminotransferase (alt) more than 1.5 times that of the upper limit of normal) * participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality * participant who has drug allergy history and anaphylactic reaction * participant who took oral contraceptive in 6 months * participant who used any drug (including chinese herbal medicine) within 1 week. * participant who donated blood within 2 months * participant who participated clinical trials of any drug in 3 months (as subjects) * participant who has any positive result of virus serology check: human immunodeficiency virus antigen antibody (hiv ag/ab) and hepatitis c virus (hcv) - immunoglobulin g(igg) antibody to igg, hepatitis b surface antigen (hbsag) and treponema pallidum antibody (tp) * participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse * participant who the researchers believe that there are volunteers who are not suitable for the study
the effect of pregabalin on postoperative pain and opioid consumption in spine surgery

Conditions: Postoperative Pain

Summary: the effect of pregabalin on post-operative pain and opioid consumption in spine surgery, a prospective, randomized, controlled study

aim of the work: the aim of our study is to compare the analgesic effect of pre-emptive oral pregabalin 150mg on acute postoperative pain and opioid consumption in spine surgery. evaluated by visual analog scale (vas) primary outcome measure is the total amount of rescue morphine received by patients for 24h postoperatively. secondary outcome measures include level of acute postoperative pain by vas, and duration of hospital stay patients and methods : this study will be carried out after being approved from the medical research ethical committee, faculty of medicine, assiut university, assiut, egypt, and after obtaining a written informed consents from all participating patients. inclusion criteria: this prospective randomized clinical study will include eighty patients with asa i-ii, aged 18-60 years scheduled for spine surgery exclusion criteria : excluded from the study are patients with known allergy to the study drugs, significant cardiac, respiratory, renal, cns or hepatic disease, drug or alcohol abuse, pregnant women, patients refusing participation and psychiatric or mental illness that would interfere with perception and assessment of pain.

Eligibility criteria:
inclusion criteria: * : this prospective randomized clinical study will include eighty patients with asa i-ii, aged 18-60 years scheduled for spine surgery exclusion criteria: * : excluded from the study are patients with known allergy to the study drugs, significant cardiac, respiratory, renal, cns or hepatic disease, drug or alcohol abuse, pregnant women, patients refusing participation and psychiatric or mental illness that would interfere with perception and assessment of pain.

Keywords: pregabalin
vagus auricular stimulation for tinnitus

Conditions: Tinnitus

Summary: this pilot study is a randomized, double-blinded controlled trial of adult participants with chronic, moderate to severe bothersome subjective tinnitus. participants will be randomly assigned to either an active auricular stimulation device group or a sham-control group.both groups will also undergo virtual mindfulness-based stress reduction(mbsr) over 8 weeks to promote tinnitus bother reduction, and general well-being. outcome measures will be assessed at baseline, end of intervention, and at 1-month post-intervention.

adults experiencing moderate to severe tinnitus have significant impairment in their quality of life. while cognitive behavioral therapy (cbt) is the most effective treatment for tinnitus, its accessibility is limited. alternative treatment options such as masking pose significant risks and have varying success rates in achieving tinnitus cessation. given these limitations and risks, there is a need to explore alternative treatment options for tinnitus that are both effective and easily accessible. transcutaneous electrical stimulation of the vagus nerve has been explored as a treatment option for tinnitus using different study designs with varying response rate. in contrary, this pilot study will provide valuable insights and preliminary evidence for the effectiveness of transcutaneous stimulation of the auricular branch of the vagus nerve (tabvn-stim) utilizing a novel device that produces vibrational stimulation mimicking physiological sensory input to the abvn. this research provides preliminary evidence for a potentially safe, non-invasive, and easily applicable treatment option for those suffering from chronic bothersome tinnitus, ultimately improving their quality of life.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * ability to read, write, speak, and understand english * bothersome tinnitus with initial tssf score greater than 40 on screening * available for the entire period of the study including one month follow-up after completion of 8-week intervention period * access to internet-connected device(s) such as phone, tablet, or laptop with a camera exclusion criteria: * age\>70 * pregnant or planning to become pregnant during the study period * previous participation in an auricular stimulation trial * currently on active treatment for tinnitus * have cochlear implant or other device that impedes usage of auricular stimulation device * tinnitus related to ear surgery, meniere's disease, ear infections, or other ear pathology * substance abuse * unstable psychiatric disorders * patient health questionnaire (phq-9) score greater than 9 history of brain surgery * history of traumatic brain injury * history of bradycardia or bradyarythmias

Keywords: audiology otolaryngology mindfulness based stress reduction (mbsr) auricular branch of vagus nerve neuromodulation transcutaneous stimulation
open-label, multiple ascending dose study of ravulizumab (alxn1210) in participants with paroxysmal nocturnal hemoglobinuria (pnh)

Conditions: Paroxysmal Nocturnal Hemoglobinuria; PNH

Summary: the primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (iv) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with pnh.

the study consisted of a screening period of up to 30 days and a treatment period of up to 253 days for cohorts 1-3 and 281 days for cohort 4. after completion of the treatment period, all participants had the opportunity to enter the extension period, wherein participants continue to receive ravulizumab for up to 5 years. the first dose in the extension period occurred on day 253 for cohorts 1-3 and on day 281 for cohort 4. the data presented includes the primary completion date of the study for the treatment period. the results for the extension period will be reported after study completion.

Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age 2. pnh diagnosis confirmed by documented high-sensitivity flow cytometry 3. documented meningococcal vaccination not more than 3 years prior to dosing 4. female participants of childbearing potential were to use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab. 5. willing and able to give written informed consent and comply with the study visit schedule exclusion criteria: 1. treatment with a complement inhibitor at any time 2. female participants who are planning to become pregnant, or are pregnant, breastfeeding or who had a positive pregnancy test at screening or day 1 3. participation in an interventional clinical study within 30 days before initiation of dosing on day 1, or use of any experimental therapy within 30 days prior to dosing on day 1, or within 5 half-lives of the investigational product, whichever was greater 4. history of allergy to any drug, allergen, excipients of ravulizumab or known allergy to chinese hamster ovary cell proteins 5. inability to comply with study requirements 6. history of any clinically significant cardiac, hepatic, immunologic, pulmonary, or rheumatoid disease that, in the investigator's judgment, would preclude participation 7. other unspecified reasons that, in the opinion of the investigator or sponsor, make the participant unsuitable for enrollment

Keywords: complement inhibitor
effectiveness of telemedicine care replacing standard care in gestational diabetes

Conditions: Gestational Diabetes

Summary: this is a a single-centre, parallel, randomized controlled trial in women with gestational diabetes mellitus (gdm). women are randomized to routine monthly prenatal clinic care (standard care group) or a group sending daily glucose readings via an application installed on a smartphone and monthly individual videoconferences replacing in-person visits (telemedicine group). the overall aim is to compare the effectiveness of the combine synchronous and asynchronous telemedicine care with the standard care in women with gdm.

in our single-centre, parallel, randomized controlled trial in women with gestational diabetes (gdm) the investigators aim to compare the effectiveness of combined synchonous and asynchronous telemedicine care with the standard care. in the telemedicine group appointments are performed online via monthly scheduled videoconferences. women also receive a smartphone with the installed application that enable transfer of the measured capillary glucose concetration at the same time it is performed. the glucose data sent by women are reviewed once per week and after that healthcare professionals contact women if necessary. on the other hand, in the standard care group, visits are scheduled normally on a monthly basis at the diabetes clinic. intention-to-treat analysis is going to be performed. the investigators aim to compare glycemic control, gestational weight gain and perinatal data between groups. student's t-test or mann-whitney u test will be used for normally or non-normally distributed variables. differences between groups in categorical data will be calcuated by chi square.

Eligibility criteria:
inclusion criteria: * less then 30 weeks of gestation at enrolement * gdm diagnosis * at least moderate slovenian language skills * willingness to participate exclusion criteria: * more than 30 weeks of pregnancy * overt diabetes or fasting glucose \>6.9 mmol/l at diagnosis * multiple pregnancy * poor slovene language skills * history or bariatric surgery or other surgeries that induce malabsorbtion * use of systemic steroids prior to enrolment * presence of concomitant disease that could affect glucose control or self-management (e.g. uncontrolled psychiatric disorder)

Keywords: telemedicine glycemic control perinatal outcomes
oropharyngeal administration of colostrum to extremely low gestational age newborns

Conditions: Extremely Low Gestational Age Newborn; Premature Infant

Summary: colostrum is rich in cytokines and other immune agents that may provide immunomodulatory protection against nosocomial infection in extremely premature infants. however, most of them could not proceed enteral feedings due to clinical instability in the first few days. recent studies supports oropharyngeal administration as a potentially safe and effective delivery method for immunologic benefits and only small amount of colostrum could be administrated for immune therapy for extremely premature babies. the purpose of this study is to determine the beneficial effects of oropharyngeal administration of colostrum for immunologic aspects in extremely low gestational age infants and evaluated the safety of this method to extremely premature infants in the first few days of life.


Eligibility criteria:
inclusion criteria: * premature infant with a gestational age less than 28 weeks born at seoul national university hospital and admit to the seoul national university children's hospital nicu immediately after birth * parents of the infant signed to the informed consent form with voluntary agreement exclusion criteria: * infants with major congenital anomalies or chromosomal syndromes * infants of mothers not willing to provide colostrum in the first week of life * infants of mothers with known infectious diseases that may be transmitted through the breast milk such as hiv, hepatitis c or active tb
aniseikonia in epiretinal membrane patients

Conditions: Epiretinal Membrane

Summary: examination of aniseikonia in epiretinal membranes patients before and after surgery

phakic patients woth epiretinal membranes are examined for aniseikonia and refractive status before and after surgery. follow up is one year.

Eligibility criteria:
inclusion criteria: * epiretinal membrane phakic on both eyes exclusion criteria: * no previous eye surgeries * refractive status +/- 2 seq
16-week repeat oral dose study of akb-6548 for anemia in participants with end stage renal disease (esrd) requiring chronic hemodialysis

Conditions: Anemia; End Stage Renal Disease

Summary: the purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered akb-6548 in participants with end stage renal disease undergoing chronic hemodialysis.


Eligibility criteria:
key inclusion criteria: * 18 to 79 years inclusive * chronic kidney disease (ckd) stage 5 on chronic hemodialysis for at least 3 months * anemia secondary to ckd treated with erythropoiesis stimulating agent and intravenous iron key exclusion criteria: * body mass index \>44.0 kilograms per meter squared (kg/m\^2) * transfusion within 8 weeks prior to screening * alanine transaminase or total bilirubin \>1.25x uln * uncontrolled hypertension * class iii or iv congestive heart failure * myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack within 6 months prior to screening

Keywords: anemia end stage renal disease chronic kidney disease ckd dialysis chronic renal insufficiency renal impairment erythropoietin kidney oral anemia treatment hemoglobin hypoxia-inducible factor hif hypoxia-inducible factor propyl-hydroxylase inhibitor hif-phi pharmacokinetics